Apollomics (NASDAQ:APLM) is developing a pipeline of nine novel drug candidates across multiple programs, six of which are now in the clinical stage of development and two in late-stage studies.
Closely-held ImmunoBrain Checkpoint, with its R&D team in Israel, is pursuing a unique approach that targets the peripheral immune system, rather than directly targeting the brain in patients suffering from Alzheimer’s...
Anixa Biosciences (NASDAQ:ANIX) is targeting a unique technology in two early-stage, first-in-class prophylactic cancer vaccines with the potential to prevent cancer cells from forming into breast and ovarian tumors.
As CEO of the Victoria Hand Project, a charity spun out of the University of Victoria in British Columbia, Michael Peirone is a jack of all trades: engineering, operations, IP, business strategy, fundraising and...
Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...
Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...
Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...
Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”
ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.
John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...